In the Czech Republic an application has been filed, so the use of The NGAL-Test can be covered by the public healthInsurance.

The application.

This means that the Czech Republic will be the FIRST country worldwide to adapt the NGAL Test in routine diagnostics (if the application is approved)

Hopefully we will soon be able to say :   Congratulations Czech Citizens !!!

BioPorto Diagnostics is the sole player on the Czech marked, which is covered by the EPO Cutoff patent.


About Karl M. Bidstrup

Tidligere ejer af Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A) hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.